549
Participants
Start Date
December 31, 2011
Primary Completion Date
June 30, 2014
Study Completion Date
September 30, 2014
Daclatasvir
Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks
Ribavirin
Tablets; oral; for patients weighing \<75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing \>75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response
PEG-Interferon alfa 2a
Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
Local Institution, Brussels
Local Institution, Buenos Aires
Local Institution, Prov de Santa Fe
Local Institution, Antwerp
Local Institution, Darlinghurst
Local Institution, Darlinghurst Nsw
Local Institution, Parkville
Local Institution, Clayton
Local Institution, Córdoba
Icahn School Of Medicine At Mount Sinai, New York
Weill Cornell Medical College, New York
Local Institution, Torino
James J Peters Vamc, The Bronx
Upper Delaware Valley Infectious Diseases, Pc, Monticello
Local Institution, Marseille
Local Institution, Berlin
Local Institution, Córdoba
Georgetown University Hospital, Washington D.C.
Local Institution, Milan
Local Institution, Hamburg
Local Institution, Milan
Local Institution, Rio de Janeiro
Local Institution, Rio de Janeiro
Johns Hopkins University, Lutherville
Virginia Commonwealth University, Richmond
Local Institution, Brescia
University Of North Carolina At Chapel Hill, Chapel Hill
Local Institution, Madrid
Local Institution, Madrid
Local Institution, Madrid
Local Institution, Madrid
Morehead Medical Plaza, Charlotte
Orlando Immunology Center, Orlando
University Of Miami School Of Medicine, Miami
Local Institution, Pessac
Local Institution, Montpellier
University Of Alabama At Birmingham, Birmingham
Local Institution, Seville
Local Institution, Modena
Local Institution, Bonn
Local Institution, Frankfurt am Main
Local Institution, Frankfurt
Local Institution, Paris
Local Institution, Paris
Local Institution, Paris
Amelia Court Hiv Research Clinic, Dallas
Local Institution, Paris
Local Institution, Paris
Baylor College Of Medicine, Houston
Texas Liver Institute, San Antonio
Southern California Permanente Medical Group, Los Angeles
Local Institution, Porto Alegre
Scripps Clinic, La Jolla
Ucsd Antiviral Research Center, San Diego
Desert Medical Group Inc., Palm Springs
San Francisco Gen Hosp, San Francisco
Kaiser Permanente Medical Center, San Francisco
Local Institution, Moscow
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Kaluga
Local Institution, Lipetsk
Local Institution, Volgograd
Local Institution, Saratov
Local Institution, Nizhny Novgorod
Va Connecticut Healthcare System, West Haven
Saint Michael'S Medical Center, Newark
Local Institution, Buenos Aires
Local Institution, Ciudad de Buenos Aires
Local Institution, Brussels
Local Institution, São Paulo
Local Institution, Edmonton
Local Institution, Vancouver
Local Institution, Vancouver
Local Institution, Victoria
Local Institution, Ottawa
Local Institution, Torono
Local Institution, Montreal
Local Institution, Montreal
Local Institution, Montreal
Fundacion De Investigacion De Diego, San Juan
University Of Puerto Rico School Of Medicine, San Juan
Local Institution, Badalona
Local Institution, Barcelona
Local Institution, London
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY